Cue Biopharma stock falls after pricing capital raise of $20M via securities offering
Source: SeekingAlpha
2025-04-15 01:32:46 ET
Cue Biopharma ( NASDAQ: CUE ) announced the pricing details of its underwritten public offering. The offering includes (i) 13,530,780 shares of its common stock, along with warrants to purchase an additional 3,382,695 shares, and (ii) for certain investors, pre-funded warrants to acquire 11,469,216 shares of common stock, also with accompanying warrants to purchase 2,867,304 more shares....
Read the full article on Seeking Alpha
For further details see:
Cue Biopharma stock falls after pricing capital raise of $20M via securities offering
Cue Biopharma Inc.
NASDAQ: CUE
CUE Trading
-3.24% G/L:
$0.3139 Last:
1,339,487 Volume:
$0.309 Open:
CUE Latest News
March 09, 2026 08:00:00 am
Cue Biopharma to Present New In vitro Data for CUE-401 at the 20th World Immune Regulation Meeting (WIRM) 2026
February 17, 2026 08:00:00 am
Cue Biopharma Announces Preclinical Safety and Tolerability Data for CUE-401 for the Treatment of Autoimmune and Inflammatory Diseases
February 12, 2026 08:00:00 am
Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Financial and Business Officer
CUE Stock Data
$30,117,989
80,549,371
0.16%
23
N/A
Biotechnology & Life Sciences
Healthcare
US
Boston
